ZTS vs. HZNP, BMY, PFE, MRK, REGN, VRTX, GSK, TAK, SNY, and GMAB
Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Horizon Therapeutics Public (HZNP), Bristol-Myers Squibb (BMY), Pfizer (PFE), Merck & Co., Inc. (MRK), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), GSK (GSK), Takeda Pharmaceutical (TAK), Sanofi (SNY), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical preparations" industry.
Zoetis vs.
Horizon Therapeutics Public (NASDAQ:HZNP) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.
In the previous week, Horizon Therapeutics Public had 8 more articles in the media than Zoetis. MarketBeat recorded 10 mentions for Horizon Therapeutics Public and 2 mentions for Zoetis. Zoetis' average media sentiment score of 0.81 beat Horizon Therapeutics Public's score of 0.47 indicating that Zoetis is being referred to more favorably in the news media.
Zoetis has higher revenue and earnings than Horizon Therapeutics Public. Zoetis is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.
Horizon Therapeutics Public currently has a consensus price target of $111.42, indicating a potential upside of 12.07%. Zoetis has a consensus price target of $221.14, indicating a potential upside of 34.61%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Horizon Therapeutics Public.
Zoetis has a net margin of 25.59% compared to Horizon Therapeutics Public's net margin of 10.40%. Zoetis' return on equity of 50.26% beat Horizon Therapeutics Public's return on equity.
91.0% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 90.2% of Zoetis shares are owned by institutional investors. 2.5% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 0.1% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Horizon Therapeutics Public has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Horizon Therapeutics Public received 26 more outperform votes than Zoetis when rated by MarketBeat users. Likewise, 78.15% of users gave Horizon Therapeutics Public an outperform vote while only 77.57% of users gave Zoetis an outperform vote.
Summary
Zoetis beats Horizon Therapeutics Public on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools